Mesoblast Limited
MSB.AX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.83B
Close$
Share Statistics
| Market cap | $1.83 Billion |
|---|---|
| Enterprise Value | $1.85 Billion |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | -10.12% |
|---|---|
| Return on Assets | -7.44% |
| Return on Invested Capital | -7.41% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 15.39 |
| Enterprise Value to EBIT | -36.11 |
| Enterprise Value to Net Income | -33 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.22 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 26, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$76.60 M
Average shareholder expectationNext Earnings Call
Expected Date
March 4, 2027
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$125.99 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Mesoblast Ltd
108 employees
CEO: Silviu Itescu Mesoblast Limited, an Australian biopharmaceutical company established in Melbourne in 2004, specializes in the development and global commercialization of allogeneic cellular medicines. With operations spanning the United States, Austra...